BiomX Inc. (PHGE)

IL — Healthcare Sector
Peers: KRBP  ZVSA  YS  NAVB    IMMX  CNSP  EFTR  SONN  LABP  APGN  ANGN 

Automate Your Wheel Strategy on PHGE

With Tiblio's Option Bot, you can configure your own wheel strategy including PHGE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol PHGE
  • Rev/Share 0.0013
  • Book/Share -0.303
  • PB 1.488
  • Debt/Equity 0.3793
  • CurrentRatio 0.0
  • ROIC 6.2892

 

  • MktCap 13669264.0
  • FreeCF/Share -0.4923
  • PFCF -0.3978
  • PE -3.0316
  • Debt/Assets 0.0
  • DivYield 0
  • ROE -0.422

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 4
  • P/B Score 3
  • D/E Score 2

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
No ratings available.

News

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
PHGE
Published: May 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) Presentation to Focus on Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Read More
image for news BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference
BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
PHGE
Published: May 08, 2025 by: GlobeNewsWire
Sentiment: Neutral

NESS ZIONA, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Thursday, May 15, 2025, at 2:00 p.m. ET, to report first quarter 2025 financial results and provide business and program updates.

Read More
image for news BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025
BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
PHGE
Published: April 18, 2025 by: Zacks Investment Research
Sentiment: Positive

BiomX (PHGE) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Read More
image for news BiomX (PHGE) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
PHGE
Published: March 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

NESS ZIONA, Israel, March 25, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE, the “Company” or “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced financial results for the fourth quarter and full year ended December 31, 2024, and provided program and business updates.

Read More
image for news BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates
BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025
PHGE
Published: March 19, 2025 by: GlobeNewsWire
Sentiment: Neutral

NESS ZIONA, Israel, March 19, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will report fourth quarter and full year 2024 financial results and provide business and program updates on Tuesday, March 25, 2025.

Read More
image for news BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

About BiomX Inc. (PHGE)

  • IPO Date 2019-03-13
  • Website https://www.biomx.com
  • Industry Biotechnology
  • CEO Mr. Jonathan Eitan Solomon MBA
  • Employees 52

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.